Research supporting Relevance of Sengenics Krex™ technology

Research

Study Design:

Metastatic melanoma, BRAF mutant patients, treated with experimental checkpoint inhibitor drugs.

Results:

Stratified patients into 3 cohorts (responsive, non-responsive, toxic).

Published study:

Development Of A Novel, Quantitative Protein Microarray Platform for the Multiplexed Serological Analysis of Autoantibodies to Cancer-Testis Antigens

Study Design:

Identification of novel autoantibodies in SLE and stratification of subgroups of SLE individuals.

Results:

4 SLE subgroups were categorised based on hierarchical clustering and principal component analysis (PCA) with known autoantigens such as TROVE2 (Ro60) and SSB (La) forming a single cluster and novel TGF-β signalling (SMAD2 and SMAD5) and TLR signalling (My88) autoantigens forming another cluster.

Published study:

Autoantibodies Targeting TLR and SMAD Pathways Define New Subgroups in Systemic Lupus Erythematosus

Study Design:

p53 microarray printed onto a neutravidin-derivatised dextran hydrogel surface probed with Cy3-labelled GADD45 duplex oligo

Results:

Quantitative parallel thermodynamic analysis revealed previously unknown functional effects of mutation on p53 protein-DNA interaction
Differential DNA binding activity of p53 mutant proteins
Quantitative analysis unravels mechanistic differences between ‘loss of function’ mutations

Published study:

Functional protein microarrays for parallel characterisation of p53 mutants

Study Design:

Sample type:
- Plasma from Colorectal cancer and healthy normal individuals
- Tissue from Colorectal cancer individuals (cancer and adjacent normal tissue)
Platform:
- Sengenics KREX CT100+ microarray
- Orvar™ Autoproteome™ Discovery technology

Results:

Breakdown of Selected/Identified Antigens

The Orvar™ technology identified a total of 28 unique autoantigens (Figure 2) which had corresponding autoantibodies present in Colorectal cancer patients;
This Orvar™ Colorectal library also led to the discovery of homologues to the antigens eliciting high autoantibody responses on KREX microarrays. These homologues may contain overlapping surface epitopes reactive to these autoantibodies;
As all antigens immobilised onto the KREX microarrays are present as wild-type forms, the unique antigens on Orvar™ which are also on KREX microarrays suggests detection of mutated forms of these antigens using the Orvar™ technology.

FEATURED PRODUCTS